Skip to content

A PROSPECTIVE RANDOMISED COMPARATIVE STUDY OF HYPERBARIC ROPIVACINE VS HYPERBARIC LEVOBUPIVACAINE IN SPINAL ANAESTHESIA

A COMPARATIVE STUDY OF HYPERBARIC ROPIVACAINE VS HYPERBARIC LEVOBUPIVACAINE IN SPINAL ANAESTHESIA - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/078662
Enrollment
80
Registered
2024-12-27
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: 4- Measurement and Monitoring

Interventions

Intervention1: Hyperbaric Ropivacaine 0.75% in Spinal Anaesthesia: Dose - 3cc of 0.75% Hyperbaric Ropivacaine Route of Administration - Subarachnoid Space Control Intervention1: Hyperbaric Levobupi

Sponsors

D Y Patil University School of Medicine and Hospital Nerul Navi Mumbai
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient undergoing various infra-umbilical surgeries under spinal anaesthesia ,Asa grade 1 and 2, Age 18-60 years

Exclusion criteria

Exclusion criteria: Refusal ofspinal anaesthesia Asa grade 3 and 4 Head injury and raised ICP Psychiatric diseases Known allergy to test drug Infection at site of injection Uncontrolled hypovolemia Coagulopathies Fixed cardiac output ststes

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of Ropivacaine and Levobupivacaine based on : a)Onset and duration of sensory blockade b)Onset and duration of motor blockade Timepoint: To compare the efficacy of Ropivacaine and Levobupivacaine based on : a)Onset and duration of sensory blockade b)Onset and duration of motor blockade

Secondary

MeasureTime frame
To compare in the two groups: 1)Maximum height of sensory blockade, 2) Hemodynamic effects 3)Complications or side effects if any . Timepoint: In 3 hours

Countries

India

Contacts

Public ContactDR ANURADHA MALLIWAL

DR D Y PATIL UNIVERSITY AND SCHOOL OF MEDICINE

anumalliwal@gmail.com9920318482

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026